Rethinking Meaningful Clearance in Clinical Research

A panelist discusses how Psoriasis Area and Severity Index score of 90% improvement (PASI 90) may no longer fully capture the evolving standards of therapeutic success, suggesting PASI 100 as the next benchmark for meaningful clearance. They highlight the growing expectation for near-total skin clearance as trial designs continue to evolve with more potent agents.

A panelist discusses how durability of remission is emerging as a critical factor in long-term psoriasis management, calling for extended follow-up beyond current pivotal trials. They emphasize that oral systemics may influence both patient recruitment and trial design by attracting broader, more diverse populations compared with injectables.

A panelist discusses how the dermatology field must prioritize monitoring for malignancy, cardiovascular events, and other long-term safety events while pursuing innovative trial designs that mirror real-world clinical practice. The expert predicts these adaptations will help balance efficacy with safety and better guide long-term therapeutic decision-making.